Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GXO Logistics Inc (GXO) vs Novo Nordisk A/S (NVO) Price & Performance

GXO Logistics IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

GXO Logistics Inc vs Novo Nordisk A/S — how do they compare? GXO Logistics Inc trades at $54.2 (market cap $6.02B), while Novo Nordisk A/S trades at $50.65 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 36.9× GXO Logistics Inc's market cap, and Novo Nordisk A/S pays a 3.56% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.

GXONVO
Market Cap
$6.02B$222.24B
Sector
IndustrialsHealth
52-Week High
$65.59$71.70
52-Week Low
$45.52$35.29
Enterprise Value
$11.18B$241.20B
Dividend Yield
3.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GXO Logistics Inc

GXO Logistics is trading at $53.36, up 7.43% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamental performance with three consecutive quarterly earnings beats and 10.8% revenue growth in Q1 2026. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $66.60 consensus price target representing 25% upside potential. Recent business developments include multiple partnership renewals and expansion into strategic verticals like aerospace and defense.

GXO presents a compelling investment opportunity with strong earnings momentum and institutional support, though investors should monitor competitive pressures from Amazon's logistics expansion and the company's transition toward higher-margin verticals. The stock's current valuation at 46.69x P/E appears elevated relative to modest net margins, requiring continued execution on growth initiatives to justify premium multiples.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.

Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GXO Logistics Inc

GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.

Read more on GXO

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO